Radioimmimotherapy in high grade gliomas

M. Bartolomei, C. Grana, M. Ferrari, A. Boiardi, M. Chinol, G. Paganelli

Research output: Contribution to journalArticle

Abstract

Despite aggressive treatments including surgery, radiotherapy and chemotherapy, the prognosis of high grade gliomas (HGG) remains poor. Since a curative option is not currently available, new therapeutic strategies are required to extend the progression-free interval and the overall survival ofglioma patients. The use of monoclonal antibodies (MoAbs) labelled with cytotoxic agents has demonstrated the potential to interfere with the growth of tumour. This article describes our experience in radioimmunotherapy (RIT) with monoclonal antibodies and tumour pretargeting with the Avidin-Biotin system, either in systemic and locoregional administrations. This therapy offers the exciting prospect of increasing the specificity of tumour cell irradiation with radionuclides. We suggest that RIT, both systemic and locoregional, should be used as part of a combined modality approach, in combination with surgery, radiotherapy and chemotherapy.

Original languageEnglish
Pages (from-to)97-104
Number of pages8
JournalRivista Medica
Volume13
Issue number4
Publication statusPublished - Dec 2007

Fingerprint

Glioma
Radioimmunotherapy
Radiotherapy
Monoclonal Antibodies
Drug Therapy
Neoplasms
Avidin
Cytotoxins
Biotin
Radioisotopes
Therapeutics
Survival
Growth

Keywords

  • Antibodies
  • Glioblastoma
  • Radioimmunotherapy

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Radioimmimotherapy in high grade gliomas. / Bartolomei, M.; Grana, C.; Ferrari, M.; Boiardi, A.; Chinol, M.; Paganelli, G.

In: Rivista Medica, Vol. 13, No. 4, 12.2007, p. 97-104.

Research output: Contribution to journalArticle

Bartolomei, M. ; Grana, C. ; Ferrari, M. ; Boiardi, A. ; Chinol, M. ; Paganelli, G. / Radioimmimotherapy in high grade gliomas. In: Rivista Medica. 2007 ; Vol. 13, No. 4. pp. 97-104.
@article{ad067949611f418db33bf8c7f9440f35,
title = "Radioimmimotherapy in high grade gliomas",
abstract = "Despite aggressive treatments including surgery, radiotherapy and chemotherapy, the prognosis of high grade gliomas (HGG) remains poor. Since a curative option is not currently available, new therapeutic strategies are required to extend the progression-free interval and the overall survival ofglioma patients. The use of monoclonal antibodies (MoAbs) labelled with cytotoxic agents has demonstrated the potential to interfere with the growth of tumour. This article describes our experience in radioimmunotherapy (RIT) with monoclonal antibodies and tumour pretargeting with the Avidin-Biotin system, either in systemic and locoregional administrations. This therapy offers the exciting prospect of increasing the specificity of tumour cell irradiation with radionuclides. We suggest that RIT, both systemic and locoregional, should be used as part of a combined modality approach, in combination with surgery, radiotherapy and chemotherapy.",
keywords = "Antibodies, Glioblastoma, Radioimmunotherapy",
author = "M. Bartolomei and C. Grana and M. Ferrari and A. Boiardi and M. Chinol and G. Paganelli",
year = "2007",
month = "12",
language = "English",
volume = "13",
pages = "97--104",
journal = "Rivista Medica",
issn = "1127-6339",
publisher = "New Magazine Edizioni S.r.l.",
number = "4",

}

TY - JOUR

T1 - Radioimmimotherapy in high grade gliomas

AU - Bartolomei, M.

AU - Grana, C.

AU - Ferrari, M.

AU - Boiardi, A.

AU - Chinol, M.

AU - Paganelli, G.

PY - 2007/12

Y1 - 2007/12

N2 - Despite aggressive treatments including surgery, radiotherapy and chemotherapy, the prognosis of high grade gliomas (HGG) remains poor. Since a curative option is not currently available, new therapeutic strategies are required to extend the progression-free interval and the overall survival ofglioma patients. The use of monoclonal antibodies (MoAbs) labelled with cytotoxic agents has demonstrated the potential to interfere with the growth of tumour. This article describes our experience in radioimmunotherapy (RIT) with monoclonal antibodies and tumour pretargeting with the Avidin-Biotin system, either in systemic and locoregional administrations. This therapy offers the exciting prospect of increasing the specificity of tumour cell irradiation with radionuclides. We suggest that RIT, both systemic and locoregional, should be used as part of a combined modality approach, in combination with surgery, radiotherapy and chemotherapy.

AB - Despite aggressive treatments including surgery, radiotherapy and chemotherapy, the prognosis of high grade gliomas (HGG) remains poor. Since a curative option is not currently available, new therapeutic strategies are required to extend the progression-free interval and the overall survival ofglioma patients. The use of monoclonal antibodies (MoAbs) labelled with cytotoxic agents has demonstrated the potential to interfere with the growth of tumour. This article describes our experience in radioimmunotherapy (RIT) with monoclonal antibodies and tumour pretargeting with the Avidin-Biotin system, either in systemic and locoregional administrations. This therapy offers the exciting prospect of increasing the specificity of tumour cell irradiation with radionuclides. We suggest that RIT, both systemic and locoregional, should be used as part of a combined modality approach, in combination with surgery, radiotherapy and chemotherapy.

KW - Antibodies

KW - Glioblastoma

KW - Radioimmunotherapy

UR - http://www.scopus.com/inward/record.url?scp=34547351425&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547351425&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:34547351425

VL - 13

SP - 97

EP - 104

JO - Rivista Medica

JF - Rivista Medica

SN - 1127-6339

IS - 4

ER -